MCHP
LONGINSIDER SELLCONGRESS BUYMICROCHIP TECHNOLOGY INC.
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q2 2026 data — frozen, no longer refreshed.
News Summary
NeutralMicrochip delivered strong operational execution through mid-2026 with consecutive earnings beats, robust 35–42% YoY revenue growth driven by industrial and data center demand, and strategic acquisitions of Hailo and Vorago to strengthen AI and radiation-hardened capabilities. However, AI-driven supply-chain constraints in Q2 2027 (revealed November 2026) compressed near-term shipment capacity and triggered significant analyst price-target cuts across major houses, signaling investor concern about demand sustainability and near-term supply dynamics despite maintained positive fundamentals.
Red flags
- •AI-driven supply shortage limiting factory capacity and pushing lead times to 6–32 weeks, reducing near-term shipment upside
- •Wave of analyst price-target cuts in November 2026 (Truist $90→$62, Raymond James $125→$80, Citi $95→$75, JPMorgan $120→$100) despite beats, indicating diminished growth confidence
- •~$53M of non-repeating revenue items in Q2 2027 inflating comparisons; December quarter guidance implies sequential decline despite favorable YoY growth
Funds Buying (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Glenview Capital | Larry Robbins | 266K | +266K | $24M | 0.5% | — | NEW |
| Soros Fund Management | Soros Family Office | 228K | +228K | $21M | 0.3% | — | NEW |
| Point72 | Steve Cohen | 145K | +145K | $11M | <0.1% | — | NEW |
| Maverick Capital | Lee Ainslie | 7K | +7K | $1M | <0.1% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where MCHP ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #35 of this fund's book
- 32BAUSCH PLUS LOMB CORP$32M
- 33BAKER HUGHES COMPANY$27M
- 34ELEVANCE HEALTH INC FORMERLY$26M
- 35MICROCHIP TECHNOLOGY INC.$24M
- 36BRUKER CORP$15M
- 37NOVARTIS AG$14M
- 38DIGITALOCEAN HLDGS INC$13M
Values are quarter-end position sizes. Shown only for funds where MCHP ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Insider Activity
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| BlackRock, Inc. | SC 13G/A | 63.3M | 11.6% | 2026-10-27 | ↗ |
| Vanguard Capital Management | SC 13G | 40.6M | 7.5% | 2026-04-30 | ↗ |
| Vanguard Portfolio Management | SC 13G | 32.5M | 6.0% | 2026-04-29 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Gilbert Cisneros | house | CA31 | BUY | $1,001 - $15,000 | 2026-06-30 | 2026-07-02 | ↗ |
Earlier trades (1) — dated outside this quarter's window, not counted in the badges
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | senate | — | BUY | $1,001 - $15,000 | 2026-03-27 | 2026-07-21 | ↗ |
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Apr 1, 2026.